Please ensure Javascript is enabled for purposes of website accessibility

Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments

By Jason Hawthorne - Jun 11, 2021 at 5:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data doesn't lie. These companies have the potential to quickly steal the spotlight.

When the Food and Drug Administration (FDA) approved Biogen's (BIIB -0.57%) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. There hadn't been a therapy approved for the disease since 2003. The drug will still have to prove its impact in a follow up study, but that could take years.

No matter how that turns out, the low bar for approval set by the FDA is likely to open the floodgates for Alzheimer's treatments. It has investors in Cassava Sciences (SAVA 2.92%) and Annovis Bio (ANVS -4.88%) excited about their candidates, which are currently in clinical trials. Here are three reasons those biotech stocks might offer better gains in the years ahead than Biogen. 

A person stands behind someone seated, both looking out of the window, smiling into the sunshine.

Image source: Getty Images.

1. Potential risk versus reward 

The first reason is simple. Biogen jumped almost 50% after Aduhelm was approved. It makes sense. The FDA's approval was a broad brush green light even for types of patients who did not participate in the clinical trials. That 50% gain translates to an additional $20 billion in market capitalization. That's even though it's unlikely insurers will cover the diagnostics, treatment, and monitoring for a cohort that the drug hasn't even been tested in. If the market thinks that's what an Alzheimer's drug is worth, there are better risk-reward propositions.

Cassava and Annovis Bio might not have an approved Alzheimer's drug, but they are well on their way. Neither of their candidates have even begun phase 3 trials, but the $2.65 billion and $511 million dollar market caps, respectively, would seem to offer a lot more upside if they get approved. To realize the potential gains, investors will have to wait. Cassava plans to initiate its phase 3 studies later this year and Annovis is still completing its phase 2 trial.

2. The efficacy data is clear

Few diseases offer a winner-take-all market no matter how well a drug performs. That said, efficacy does matter. In that category, the two smaller biotechs both appear to have the upper hand on the larger Biogen.

Biogen initially scrapped its two aducanumab phase 3 studies in early 2019, then decided to file for regulatory approval later that year after analyzing a larger data set. It turned out, one of the two identical trials met its objective for lessening cognitive and functional decline. The data showed a 6.3% improvement on the Alzheimer's Disease Assessment Scale related to cognition after a year of treatment.

Wall Street was skeptical, and at least one analyst assigned a 0% likelihood that management's plan of pushing for approval would work. Never say never. The decision to approve the drug was so controversial that two members of the FDA committee that reviewed it have since quit. That's an indication that it won't be too difficult to beat Biogen's performance.

So far, Cassava and Annovis Bio have both demonstrated better results in a shorter amount of time. Patients taking Cassava's simufilam improved their scores on the same cognitive test by 10% in a mere six months. For Annovis Bio, the improvement was 30% in only 25 days. If the results hold up, one of the two drugs may overtake Biogen's despite the recent approval. Cassava plans to initiate two phase 3 studies later this year and Annovis Bio should conclude its phase 2 in the fall.

3. Factors investors might miss

Sometimes, investors can focus so hard on the results of one drug and one disease they can miss what else a small biotech has going on. Sometimes what gets missed is just as important. For Cassava and Annovis Bio, the method of administration and potential other revenue streams make each a better investment than Biogen at this point.

First, each of their Alzheimer's drugs are orally administered. Compare that to Aduhelm's once a month infusion and it's easy to see why they have a leg up in treating patients with cognitive and behavioral issues related to the disease. As for other revenue, the two definitely have optionality -- the potential for a new business to grow out of the existing one. 

For Annovis Bio, that comes from ANVS401's ability to help patients with other neurocognitive diseases like Parkinson's. The drug clears toxins from the brain to prevent cell death. That can be applicable to multiple diseases beyond Alzheimer's. For Cassava, the optionality comes in the form of a diagnostic test. Specifically, its SavaDx blood test. It would detect Alzheimer's before symptoms like memory loss are even present. If successful, the stock might be a huge winner even if its drug isn't the blockbuster shareholders hope.

The floodgates are open

Whether Biogen is able to prove the efficacy of Aduhelm in its continuing study or another Alzheimer's drug becomes the darling of Wall Street, one thing is clear. A new era is upon us. Companies are beginning to cross the finish line and bring hope to the millions of patients and family members dealing with the disease. As human beings, we should hope they are all successful. As investors, we have to look for the best opportunities. After a big jump in shares of Biogen, the smaller companies with better results and an easier method of administration look like better stocks to buy for market-beating returns.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$216.34 (-0.57%) $-1.24
Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$26.47 (2.92%) $0.75
Annovis Bio, Inc. Stock Quote
Annovis Bio, Inc.
ANVS
$11.90 (-4.88%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.